Alpha Cognition (NASDAQ:ACOG – Get Free Report) and Organovo (NASDAQ:ONVO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.
Analyst Ratings
This is a breakdown of current ratings and price targets for Alpha Cognition and Organovo, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Cognition | 0 | 0 | 1 | 0 | 3.00 |
| Organovo | 0 | 0 | 0 | 0 | 0.00 |
Alpha Cognition presently has a consensus target price of $20.00, indicating a potential upside of 112.77%. Given Alpha Cognition’s stronger consensus rating and higher probable upside, analysts clearly believe Alpha Cognition is more favorable than Organovo.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Cognition | $2.93 million | 51.42 | -$13.77 million | ($1.20) | -7.83 |
| Organovo | $122,000.00 | 0.00 | -$14.67 million | ($10.20) | N/A |
Alpha Cognition has higher revenue and earnings than Organovo. Alpha Cognition is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
8.2% of Organovo shares are owned by institutional investors. 14.0% of Alpha Cognition shares are owned by insiders. Comparatively, 3.7% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Alpha Cognition and Organovo’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Cognition | N/A | N/A | -344.17% |
| Organovo | -10,151.64% | -346.26% | -187.53% |
Risk and Volatility
Alpha Cognition has a beta of 2.48, suggesting that its stock price is 148% more volatile than the S&P 500. Comparatively, Organovo has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.
Summary
Alpha Cognition beats Organovo on 10 of the 13 factors compared between the two stocks.
About Alpha Cognition
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
About Organovo
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
